Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics of VIAject vs RHI vs Lispro in Type 1 Diabetes
NCT01000922Phase 2Completed
- Sponsor
- Biodel Inc.
- Start
- Jun 2006
- Primary completion
- Jan 2008
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of VIAject in type 1 diabetes mellitus (T1D) (6 arms), sponsored by Biodel Inc. Primary endpoints: Maximal post prandial blood glucose concentration at 8 hours and Time to maximal post prandial glucose concentration at 8 hours. Started Jun 2006; status: completed.
02
Drugs
VIAject
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01000922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01000922.